THE CLINICAL RELEVANCE OF PARAOXONASE-1 ACTIVITY AS A NOVEL BIOMARKER IN BREAST CANCER PATIENTS TREATED WITH DOXORUBICIN WITH OR WITHOUT TRASTUZUMAB

Authors :: Elizabeth I. Thompson
Bonnie Ky
W.H. Wilson Tang
Amanda M. Smith
Biniyam G. Demissei
Source :: Journal of the American College of Cardiology. 75:669
Publication Year :: 2020
Publisher :: Elsevier BV, 2020.

Subjects :: Oncology
medicine.medical_specialty
biology
business.industry
Paraoxonase
medicine.disease
Breast cancer
Trastuzumab
Internal medicine
medicine
biology.protein
Biomarker (medicine)
Clinical significance
Doxorubicin
Cardiology and Cardiovascular Medicine
business
medicine.drug

Full Text Access

Tools